These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36430669)

  • 1. Topical Delivery of Hedgehog Inhibitors: Current Status and Perspectives.
    Pedersen KK; Høyer-Hansen MH; Litman T; Hædersdal M; Olesen UH
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laser-assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo.
    Olesen UH; Pedersen KK; Togsverd-Bo K; Biskup E; Nielsen AL; Jackerott M; Clergeaud G; Andresen TL; Haedersdal M
    Lasers Surg Med; 2024 Mar; 56(3):239-248. PubMed ID: 38311811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
    Zhu H; Lewis DJ
    Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
    Lear JT; Morris LM; Ness DB; Lewis LD
    Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
    Maier T; Kulichova D; Ruzicka T; Berking C
    J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
    Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
    Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis.
    Ge W; Chen CI; Wu N; Fury MG; Ruiz E; Jalbert JJ
    Future Oncol; 2022 Jul; 18(23):2561-2572. PubMed ID: 35735026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hedgehog signaling inhibitors in solid and hematological cancers.
    Cortes JE; Gutzmer R; Kieran MW; Solomon JA
    Cancer Treat Rev; 2019 Jun; 76():41-50. PubMed ID: 31125907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
    Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
    Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert opinion on sonidegib efficacy, safety and tolerability.
    Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
    Xie P; Lefrançois P
    J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
    Gutzmer R; Solomon JA
    Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.
    Wescott R; Samlowski W
    Curr Oncol; 2023 Oct; 30(10):9156-9167. PubMed ID: 37887561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.